05.07.2012 - Under its FP7 programme, the EU will fund a project with the aim to develop a new blood apheresis device for in vivo trapping of circulating tumour cells (CTC).
The consortium of eleven companies, universities, and research institutes is coordinated by Leon Terstappen, Professor of Medical Cell Biophysics at the University of Twente (MIRA Institute, Netherlands). CTCs detach from a primary tumour and circulate in the bloodstream. They play a crucial role in spreading tumour tissue around a patient’s body. Currently only a small quantity of CTCs can be isolated from blood sample volumes of 7.5 mL for genetic and immune phenotyping to assess the sensitivity of tumour cells towards certain therapeutics. The development project totals EUR9m, of which EUR6m are provided by the EU grant. The German specialist Leukocare will develop an extracorporeal blood apheresis column to filter the patient’s whole blood stream under the roof of the programme. This in vivo trapping will increase the sensitivity of cell counting by about 500-fold. Leukocare will receive a EUR 810,000 contribution from the grant over a period of two years to fund its developmental research.
18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.
14.09.2015 The long summer resulted in a lull in the life science sector’s stock market activities, but now the speed is picking up again. Acacia, Faron and Shield have all taken the plunge on the London Stock Exchange, while others are filing overseas.